Schrödinger

120 West 45th Street
17th Floor
New York
NY
10036-4041
United States

Tel: 503-299-1150

Website: https://www.schrodinger.com/careers

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a co-founder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.

A great company is made up of great people, and Schrödinger is no exception. Whether you’re in Administration, Sales, Finance, Law, Engineering, IT, or Science, we are always on the lookout for exceptional candidates who can join us and make our team stronger. You will find Schrödinger to be a dynamic, energetic, and fast-paced place to work, where you get to interact with some of the smartest and hardest working people you’ll ever meet. If you’ve ever had a curiosity about science, and how science can improve people’s lives, then there’s no
better place to be than Schrödinger.

Stock Exchange: NASDAQ

Stock Symbol: SDGR

91 articles with Schrödinger

Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

5/19/2022

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022.
Schrödinger to Present at Citi Biotech Virtual Co-Panel Day

5/13/2022

Schrödinger announced that management will participate at the Citi Biotech Virtual Co-Panel Day.
Schrödinger Reports First Quarter 2022 Financial Results

5/4/2022

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter of 2022.
Schrödinger to Announce First Quarter 2022 Financial Results on May 4

4/20/2022

Schrödinger will report its first quarter 2022 financial results on Wednesday, May 4, 2022, after the financial markets close.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Apr 19, 2022

4/19/2022

Schrödinger, Inc. reported that on April 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 101,715 shares of the company’s common stock to 30 newly hired employees, including six newly hired employees based in India and one newly hired employee based in Japan.
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting

4/12/2022

Schrödinger, Inc. today presented new preclinical data from its Wee1 inhibitor program in a poster session at the American Association of Cancer Research (AACR) Annual Meeting taking place in New Orleans.
Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022

3/8/2022

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its small-molecule Wee1 inhibitors will be presented during a poster session at the American Association of Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana, April 8-13, 2022.
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021

2/24/2022

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full year ended December 31, 2021, and provided its financial outlook for 2022.
Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference

2/8/2022

Schrödinger announced that management will provide a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference.
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 20, 2022

1/20/2022

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that on January 16, 2022, the company granted non-statutory stock options to purchase an aggregate of 80,675 shares of the company’s common stock to 80 newly hired employees, including 77 newly hired employees based in India.
BioTools announces a collaboration with Schrödinger aimed at accelerating the discovery and development of chiral small molecule therapeutics

1/7/2022

BioTools announces a collaboration with Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, to help chemists expedite the determination of the critical three-dimensional stereo structure.
Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz

12/21/2021

Schrödinger today announced that Joel Lebowitz is retiring from his position as chief financial officer.
Schrödinger to Participate in Five Upcoming Investor Conferences

11/22/2021

Schrödinger today announced that management will participate virtually at the following investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference.
Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company Update

11/10/2021

Schrödinger, Inc. today announced financial results for the third quarter ended September 30, 2021, and provided an update on the company.
Schrödinger to Present at Jefferies London Healthcare Conference

11/9/2021

Schrödinger to Present at Jefferies London Healthcare Conference
Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting

11/4/2021

Schrödinger , Inc. today announced that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster session at the American Society of Hematology (ASH) 63rd Annual Meeting taking place virtually and in Atlanta, Georgia, December 11-14, 2021.
MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program

10/7/2021

The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.
Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update

8/12/2021

Schrödinger, Inc. today announced financial results for the quarter ended June 30, 2021, and provided an update on the company.
Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets

8/12/2021

Nimbus Therapeutics today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.
Schrödinger Reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

7/16/2021

Schrödinger, Inc. today reported that on July 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 32,975 shares of the company’s common stock to 14 newly hired employees.

First
1
2
3
4
5
Next
Last